Molecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic Tumor

Study on the Molecular Profile and Molecular Signature of Inflammatory Myofibroblastic Tumor

Gene mutation is a research hotspot in the occurrence of multiple malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of genes related to inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.

Study Overview

• Status: Unknown
• Conditions: Inflammatory Myofibroblatic Tumor

Detailed Description

Inflammatory myofibroblastic tumor（IMT）is a rare clinical mesenchymal tissue-derived tumor, which can occur in almost all organs and soft tissues, and is characterized by low-grade or borderline tumors.

The diagnosis of inflammatory myofibroblastic tumor is mainly based on histopathology and immunohistochemistry. The treatment is resistant to conventional chemotherapy and radiotherapy. The only curative treatment is complete surgical resection. When IMT shows typical cellular structural features in pathology, the diagnosis is relatively simple. However, in the presence of atypical features, the accurate diagnosis of IMT is still a challenge. Therefore, it is necessary to explore a better diagnostic method. Secondly, there is no individualized treatment method for aggressive IMT patients who relapse and metastasize after surgery. At present, gene mutation is a research hotspot in the occurrence of various malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.

• Study Type: Observational
• Enrollment (Anticipated): 29

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Recruiting
      • Cancer center of SunYat-sen University
      • Contact: Yan Wang, M.M.; Phone Number: 86-2087343795; Email: wangyan4@sysucc.org.cn
      • Contact: Dongsheng Zhang, MD,PhD
      • Principal Investigator: Dongsheng Zhang, MD,PhD
      • Sub-Investigator: Ya Ding, M.D
      • Sub-Investigator: Ying Jin, M.D
      • Sub-Investigator: Yan wang, M.M.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

From December 2009 to July 2019, the histopathological diagnosis of inflammatory myofibroblastic tumor was confirmed by surgery or puncture at Sun Yat-sen University Cancer Center.

Description

Inclusion Criteria:

1. From December 2009 to July 2019, patients who were pathologically diagnosed with inflammatory myofibroblastic tumor by Sun Yat-sen University Cancer Center；
2. There are related pathological tissue wax blocks in Sun Yat-sen University Cancer Center;
3. Patient clinical and prognosis tracking data are available.

Exclusion Criteria:

The patient who has a clinically detectable second primary malignant tumor.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Retrospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
Inflammatory myofibroblastic tumor; tissue of Inflammatory myofibroblastic tumor lession

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Establishing gene mutation spectrum of patients with inflammatory myofibroblastic tumor	We sequenced the genes in tissue samples from patients with inflammatory myofibroblastic tumor, and then analyzed the data to obtain a gene map of this type of tumor, and provide data support for the diagnosis and treatment of the disease.	through study completion，an average of 1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Exploring molecular markers for inflammatory myofibroblastic tumor	We sequenced tissue samples from patients with inflammatory myofibroblastic tumor, and then analyzed the data to explore molecular markers of this type of tumor, and provide assistance in the diagnosis and targeted therapy of the disease.	through study completion，an average of 1 year

Collaborators and Investigators

• Sponsor: Sun Yat-sen University
• Investigators: Principal Investigator: Dongsheng Zhang, PhD, Sun Yat-sen University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2020
• Primary Completion (Anticipated): January 1, 2021
• Study Completion (Anticipated): January 1, 2021

Study Registration Dates

• First Submitted: September 15, 2020
• First Submitted That Met QC Criteria: September 26, 2020
• First Posted (Actual): October 1, 2020

Study Record Updates

• Last Update Posted (Actual): October 1, 2020
• Last Update Submitted That Met QC Criteria: September 26, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: IMT; gene; molecular profiling and molecular markers
• Other Study ID Numbers: Molecular profiling of IMT

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No